Insilico Medicine Wechat Account
30.05.2025
Recently, Insilico Medicine published research in Nature Communications (Impact Factor: 14.7) detailing a novel ENPP1 small-molecule inhibitor designed using its AI-driven target discovery engine PandaOmics and generative chemistry platform Chemistry42. Preclinical validation confirmed the compound effectively and safely modulates the cGAS-STING pathway, offering a promising innovative strategy for immunotherapy.
Disclaimer
Investment Involves risk. Past performance does not represent future performance. Investor should read the product’s Prospectus for details and risk factors before making investment decision. The contents of this website is prepared and maintained by Mirae Asset Capital (China) Limited. This material has not been reviewed by the Securities and Futures Commission. Certain information contained in this website is compiled from third party sources. Whilst we have, to the best of its endeavor, ensured that such, information is accurate, complete and up-to-date, and has taken care in accurately reproducing the information. We accepts no liability for, any loss or damage of any kind resulting out of the unauthorized use of this website.
Sep 28, 2025
